Phosphodiesterase inhibitors as anti-cancer drugs

Biochemical Pharmacology

Volumn 68, Issue 6, 2004, Pages 981-988

  Hirsh, Liron ^a   Dantes, Ada ^a   Suh, Byong Sun ^b   Yoshida, Yoshio ^c   Hosokawa, Kumiko ^c   Tajima, Kimihisa ^c   Kotsuji, Fumikazu ^c   Merimsky, Ofer ^d   Amsterdam, Abraham ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Handong University   (South Korea)

^c UNIVERSITY OF FUKUI   (Japan)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Apoptosis; MDM2 transformed granulosa cell line; Methylxantines; Non small cell lung cancer (NSCLC); P53; RAS

Indexed keywords

AMINOPHYLLINE; ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE; PACLITAXEL; PHOSPHODIESTERASE INHIBITOR; THEOPHYLLINE;

APOPTOSIS; BIOTRANSFORMATION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOMA CELL; CELL DEATH; CONCENTRATION RESPONSE; CONFERENCE PAPER; CYTOTOXICITY; DRUG EFFICACY; HUMAN; LUNG CARCINOMA; NEPHROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REDUCTION; SCREENING TEST; SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; OVARIAN NEOPLASMS; PHOSPHODIESTERASE INHIBITORS; THEOPHYLLINE; TUMOR CELLS, CULTURED; XANTHINES;

EID: 4143103820     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.05.026     Document Type: Conference Paper

References (56)

1. Calabresi P, Chabner BA. Antineoplastic agents. In: Gilman AD, Rall TW, editors. Good man and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press; 1990. p. 1249-63.
2. Loo TL, Freireich EJ. Cancer chemotherapeutic drugs. In: Munson PL, editor. Principles of pharmacology. New York: Chapmann & Hall; 1995. p. 1475-1516.
3. Vermorken J.B., ten Bokkel Huinik W.W., Eisenhauer E.A., Favalli G., Belpomme D., Conte P.F., et al. Carboplatin versus cisplatin. Ann. Oncol. 4:1993;41-48
4. Fichtinger-Schepman A.M., van der Verr J.L., den Hartog J.H., Lohman P.H., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation. Biochemistry. 24:1985;707-713
5. Sorenson C.M., Eastman A. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res. 48:1988;6703-6707
6. VaisM A., Varchenko M., Said I., Chaney S.G. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry. 27:1997;54-64
7. Henkels K.M., Turchi J.J. Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. Cancer Res. 57:1997;4488-4492
8. Yoshida Y., Hosokawa K., Dantes A., Tajima K., Kotsuji F., Amsterdam A. Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene. Int. J. Oncol. 17:2000;227-235
9. Bhat S.G., Mishra S., Mei Y., Nie Z., Whitwort C.A., Rybak L.P., et al. Cisplatin up-regulates the adenosine A1 receptor in the rat kidney. Eur. J. Pharmacol. 442:2002;251-264
10. Huang P., Plunkett W. Fludarabine and gemcitibine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother. Pharmacol. 36:1995;181
11. Cartee L., Kucera G.L. Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer Chemother. Pharmacol. 41:1998;403-412
12. Orlando M., Mandachain M. Gemcitabine in ovarian cancer. Semin. Oncol. 28(Suppl. 10):2001;62-69
13. Ozols R.F. The current role of gemcitabine in ovarian cancer. Semin. Oncol. 28(Suppl. 7):2001;18-24
14. Bourgeois H., Billiart I., Chabrun V., Chieze S., Lemerre D., Ferrand V., et al. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma. Am. J. Clin. Oncol. 27:2004;89-95
15. De Lange S.M., Van Groeningen C.J., Kroep J.R., Van Bochove A., Snijders J.F., Peters G.J., et al. Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann. Oncol. 15:2004;484-488
16. Novarino A., Chiappino I., Bertelli G.F., Heouaine A., Ritorto G., Bellone G., et al. Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Ann. Oncol. 15:2004;474-477
17. Kollmannsberger C., Beyer J., Liersch R., Schoeffski P., Metzner B., Hartmann J.T., et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J. Clin. Oncol. 22:2004;108-114
18. Tortora G., Di Isemia G., Sandomencio C., Bianco R., Pomatico G., Pepe S., et al. Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res. 57:1997;5107-5111
19. Rall TW. Drugs used in the treatment of asthma. In: Gilman AD, Rall TW, editors. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press; 1990. p. 618-37.
20. Dent G., Magnussen H., Rabe K.F. Cyclic nucleotide phosphodiesterases in the human lung. Lung. 172:1994;129-146
21. Barnes PJ, Mueller RA. Bronchdilators. In: Munson PL, editor. Principles of pharmacology. New York: Chapman & Hall; 1995. p. 590-8.
22. Weinberger M., Hendeles L., Bighley L. The relation of product formulation to absorption of oral Theophylline. New Engl. J. Med. 299:1978;852-857
23. Weinberger M., Hendeles L. Theophylline in asthma. New Engl. J. Med. 334:1996;1380-1387
24. Li W., Choy D.F., Lam M.S., Morgan T., Sullivan M.E., Post J.M. Use of cultured cells of kidney origin to assess specific cytotoxic effects of nephrotoxins. Toxicol. In Vitro. 17(1):2003;107-113
25. Vanderhyden BC, Shaw TJ, Garson K, Tonary AM. In: Leung Peter CK, Adashi Eli Y, editors. Ovarian carcinoma, 2nd ed. UK: Elsevier Acadenic Press; 2004. p. 591-612 [chapter 36].
26. Fraser M, Tsang BK. In: Leung Peter CK, Adashi Eli Y, editors. The role of X-linked inhibitor of apoptosis protein in chemoresistant ovarian cancer, 2nd ed. UK: Elsevier Acadenic Press; 2004. p. 613-24 [chapter 37].
27. Amsterdam A, Sasson R. In: Leung Peter CK, Adashi Eli Y, editors. Generation and application of ovarian steroidogenic cell lines, 2nd ed. UK: Elsevier Academic Press; 2004. p. 389-409 [chapter 22].
28. Sculier J.P., Lafitte J.J., Berghmans T., Van Houtte P., Lecomte J., Efremidis A., et al. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann. Oncol. 5:2004;399-409
29. Cloven N.G., Kyshtoobayeva A., Burger R.A., Yu I.R., Fruehauf J.P. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol. Oncol. 92:2004;160-166
30. Papadimitriou C.A., Fountzilas G., Aravantinos G., Kalofonos C., Moulopoulos L.A., Briassoulis E., et al. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated. Gynecol. Oncol. 92:2004;152-159
31. Maenpaa J.U. Docetaxel: promising and novel combinations in ovarian cancer. Br. J. Cancer. 89(Suppl. 3):2003;S29-S34
32. Cartee L., Kucera G.L., Willingham M.C. Induction of apoptosis by gemcitabine in BG-1 human ovarian cancer cells compared with induction by staurosporine, paclitaxel and cisplatin. Apoptosis. 3:1998;439-449
33. Muggia F., Lu M.J. Emerging treatments for ovarian cancer. Expert Opin. Emerg. Drugs. 8:2003;203-216
34. Liew K.J., Chow V.T. Differential display RT-PCR analysis of ECV304 endothelial-like cells infected with dengue virus type 2 reveals messenger RNA expression profiles of multiple human genes involved in known and novel roles. J. Med. Virol. 72:2004;597-609
35. Youdim K.A., Qaiser M.Z., Begley D.J., Rice-Evans C.A., Abbott N.J. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic. Biol. Med. 36:2004;592-604
36. Murata J., Ayukawa K., Ogasawara M., Watanabe H., Saiki I. Induction of autocrine factor inhibiting cell motility from murine B16-BL6 melanoma cells by alpha-melanocyte stimulating hormone. Int. J. Cancer. 80:1999;889-895
37. Timoshenko A.V., Xu G., Chakrabarti S., Lala P.K., Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp. Cell Res. 289:2003;265-274
38. Santibanez J.F., Olivares D., Guerrero J., Martinez J. Cyclic AMP inhibits TGFbeta1-induced cell-scattering and invasiveness in murine-transformed keratinocytes. Int. J. Cancer. 107:2003;715-720
39. Yamanaka Y., Mammoto T., Kirita T., Mukai M., Mashimo T., Sugimura M., et al. Epinephrine inhibits invasion of oral squamous carcinoma cells by modulating intracellular cAMP. Cancer Lett. 176:2002;143-148
40. Allam M., Bertrand R., Zhang-Sun G., Pappas J., Viallet J. Cholera toxin triggers apoptosis in human lung cancer cell lines. Cancer Res. 57:1997;2615-2618
41. Shafer S.H., Phelps S.H., Williams C.L. Reduced DNA synthesis and cell viability in small cell lung carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 56:1998;1229-1236
42. Iwamoto Y., Reich R., Nemeth G., Yamada Y., Martin G.R. Cyclic AMP decreases chemotaxis, invasiveness and lung colonization of H-ras transformed mouse fibroblasts. Clin. Exp. Metastasis. 1:1993;492-501
43. Merimsky O, Hirsh L, Dantes A, Land-Bracha A, Suh BS, Amsterdam A. Induction of apoptosis in non-small lung carcinoma cell line (H1299) by combination of anti-asthma drugs with gemcitabine and cisplatin. 2004; in press.
44. Yoh K., Ishii G., Yokose T., Minegishi Y., Tsuta K., Goto K., et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin. Cancer Res. 10:2004;1691-1697
45. Okouoyo S., Herzer K., Ucur E., Mattern J., Krammer P.H., Debatin K.M., et al. Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. Int. J. Cancer. 108:2004;580-587
46. Pectasides D., Mylonakis N., Farmakis D., Nikolaou M., Koumpou M., Katselis I., et al. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer. Anticancer Res. 23:2003;4205-4211
47. Bunn PA, LeChevalier T. Lung cancer research: new combinations and the emerging role of gemcitabine. Semin Oncol 1998;25(4 (Suppl 9)):1.
48. Rapp E., Pater J.L., Willan A. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer. Report of a Canadian multicenter randomized trial. J. Clin. Oncol. 6:1988;633-641
49. NSCLC Collaborative Group: chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
50. Stork P.J., Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12:2002;258-266
51. Shmueli A., Oren M. Regulation of p53 by Mdm2: fate is in the numbers. Mol. Cell. 13:2004;4-5
52. Hosokawa K., Aharoni D., Dantes A., Shaulian E., Schere-Levy C., Atzmon R., et al. Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells. Endocrinology. 139:1998;4688-4700
53. Glenn H.L., Jacobson B.S. Cyclooxygenase and cAMP-dependent protein kinase reorganize the actin cytoskeleton for motility in HeLa cells. Cell Motil. Cytoskeleton. 55:2003;265-277
54. Sasson R., Amsterdam A. Stimulation of apoptosis in human granulosa cells from in vitro fertilization patients and its prevention by dexamethasone: involvement of cell contact and bcl-2 expression. J. Clin. Endocrinol. Metab. 87:2002;3441-3451
55. Liu F., Verin A.D., Borbiev T., Garcia J.G. Role of cAMP-dependent protein kinase A activity in endothelial cell cytoskeleton rearrangement. Am. J. Physiol. Lung Cell Mol. Physiol. 280(6):2001;L1309-L1317
56. Dent G., Magnussen H., Rabe K.F. Cyclic nucleotide phosphodiesterases in the human lung. Lung. 172:1994;129-146